16th week of 2013 patent applcation highlights part 33 |
Patent application number | Title | Published |
20130095046 | Method And Composition For Improving Skin Barrier Function - The invention relates to a method for improving skin lipid barrier function by applying to the skin a composition comprising effective amounts of a protease inhibitor and a cell differentiation enhancer. The composition is useful in promoting skin lipid barrier repair and maintaining the integrity of the lipid barrier. In this regard, the compositions can be used in the treatment and prevention of dry skin, and associated chrono/proto-aging conditions, in the treatment and prevention of irritation on the skin, in the treatment and prevention of UV-related damage to the skin, and in the enhancement of the retention of self-tanning. | 2013-04-18 |
20130095047 | COSMETIC COMPOSITION - A cosmetic composition including: (i) at least one amphiphilic copolymer; and (ii) one or more cosmetically acceptable diluents, excipients or carriers; wherein the amphiphilic copolymer is selected from the group consisting of a graft copolymer including a hydrophobic straight or branched chain carbon-carbon backbone having at least one hydrophilic side chain attached thereto; a graft copolymer comprising a hydrophilic straight or branched chain backbone having at least one hydrophobic side chain attached thereto; a block copolymer including at least one hydrophilic block and at least one hydrophobic block in a straight or branched chain backbone; and a cross-linked/network copolymer. | 2013-04-18 |
20130095048 | CYSTEINE DERIVATIVE - Cysteine compounds represented by the following formula | 2013-04-18 |
20130095049 | ANTIOXIDANT COMPOSITION - The present invention relates to an antioxidant composition comprising a combination of galatomannan and N-acetyl cysteine for its use in the treatment of a skin disease or condition resulting from reactive oxygen species production in the skin or involving reactive oxygen species production in the skin, to a hydrogel containing said combination as well as to dressing wounds comprising said hydrogel and its use in the healing of ulcers, wounds, burns and scalds. | 2013-04-18 |
20130095050 | TOPICAL SUNSCREEN COMPOSITIONS - Substantially anhydrous compositions including at least 10% by weight of a C | 2013-04-18 |
20130095051 | AVERMECTIN/METRONIDAZOLE COMPOSITIONS FOR TREATING AFFLICTIONS OF THE SKIN, E.G., ROSACEA - Pharmaceutical/dermatological compositions containing at least one avermectin compound, e.g., ivermectin and metronidazole or salt, ester or derivative thereof, are useful for treating afflictions of the skin, especially rosacea. | 2013-04-18 |
20130095052 | TOPICAL USE OF THIAZOLIDINE DERIVATIVES AGAINST CONSEQUENCES OF OXIDATIVE STRESS OF SKIN - The invention concerns a cosmetic care method for opposing destructive effects of oxidative stress and its toxic by-products, comprising administering topically to a patient in need thereof, a derivative of formula (I): | 2013-04-18 |
20130095053 | REGULATION OF SKIN PIGMENTATION BY NEUREGULIN-1 (NRG-1) - Disclosed herein are compositions and methods of using such compositions to modulate pigmentation and proliferation of a melanocyte, such as to prevent or treat skin disorders, including skin cancer or for use for cosmetic purposes. In one example, a method of modulating pigmentation of a melanocyte includes contacting the melanocyte (such as a human melanocyte) with an agent that modulates neuregulin-1 (NRG-1) activity, such as an agent that increases or decreases NRG-1 activity, thereby modulating pigmentation of the melanocyte. In one particular example, the method of increasing melanocyte pigmentation or proliferation can be used to reduce UV skin damage, including that associated with skin cancer. In another example, the method of decreasing melanocyte pigmentation can be used to treat a skin pigmentation disorder associated with undesired increased skin pigmentation. | 2013-04-18 |
20130095054 | COPOLYMERS - Described herein are copolymers comprising at least one first water-soluble monomeric unit, at least one second water-soluble monomeric unit, and at least one monomeric unit containing a basic residue. | 2013-04-18 |
20130095055 | COMPOSITIONS AND METHODS FOR MITIGATING ADVERSE EFFECTS OF EXPOSURE TO OXIDIZERS, SUCH AS CHLORINATING AND/OR BROMINATING AGENTS - Disclosed are methods of mitigating the effects of exposure to oxidizing agents, chlorinating and/or brominating agents on biological and/or synthetic fibers, by treating the body and/or clothing fibers with an effective amount of a composition comprising compounds of formula A. Also disclosed are compositions comprising compounds of formula A, for use in treating biological and/or synthetic fibers to mitigate the effects of exposure to chlorinating and/or brominating agents. | 2013-04-18 |
20130095056 | HAIR CARE COMPOSITION - A personal care composition comprising: i) a cleaning phase comprising a cleansing anionic surfactant which is a salt and comprises an alkyl group with from 8 to 14 carbons; ii) an aqueous conditioning gel network having no overall charge or being anionic, the gel network comprising: (a) fatty material; (b) a gel network anionic surfactant comprising an alkyl group with from 16 to 30 carbons; (c) cationic surfactant; (d) an active material selected from fragrances, vitamins, sunscreens and cooling agents; and iii) a cationic deposition polymer. | 2013-04-18 |
20130095057 | COMPOUNDS FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE-ASSOCIATED DISEASE - Disclosed are compounds of formula (I): | 2013-04-18 |
20130095058 | ANTIMICROBIAL COMBINATIONS OF PYRION COMPOUNDS WITH POLYETHYLENEIMINES - The present invention relates to combinations of the pyrion compounds sodium pyrithione and 1-hydroxy-2-pyridinone, and polyethyleneimines (PEI) which provide an improved biocidal effect. More particularly, the present invention relates to compositions comprising a combination of a pyrion compound selected from sodium pyrithione and 1-hydroxy-2-pyridinone together with polyethyleneimines; in respective proportions to provide a synergistic biocidal effect. Compositions comprising these combinations are useful for the protection of any living or non-living material, such as crops, plants, fruits, seeds, objects made of wood, thatch or the like, engineering material, biodegradable material and textiles against deterioration due to the action of microorganisms such as bacteria, fungi, yeasts, algae, viruses, and the like. | 2013-04-18 |
20130095059 | INHALED NO DONOR KMUPS DERIVATIVE PREVENTING ALLERGIC PULMONARY VASCULAR AND BRONCHIAL INFLAMMATION VIA SUPPRESSED CYTOKINES, INOS AND INFLAMMATORY CELL COUNTS IN ASTHMA MODEL - A method for treating a disease is provided. The method includes steps of: providing a subject in need thereof; and administering one selected from a group consisting of KMUPS compound represented by formula I, a pharmaceutically acceptable salts thereof; and a pharmaceutical composition thereof to the subject in a dosage from 1 to 2.5 milligram per kilogram of body weight, | 2013-04-18 |
20130095060 | PHARMACEUTICAL COMPOSITION FOR PROMOTING ARTERIOGENESIS, AND PREPARATION METHOD AND APPLICATIONS FOR THE SAME - The present invention relates to a pharmaceutical composition for promoting arteriogenesis, and preparation method and applications of the same, wherein said pharmaceutical composition comprises an effective amount of a drug, and a peptide hydrogel, and it forms a microenvironment for autologous cell recruitment and tissue regeneration. | 2013-04-18 |
20130095061 | UMBILICAL CORD STEM CELL SECRETED PRODUCT DERIVED TOPICAL COMPOSITIONS AND METHODS OF USE THEREOF - Compositions including topical formulations comprising secreted products obtained from the culture medium of human umbilical cord stem cells and particular combinations of components therefrom are provided for treatment of various dermatological conditions, such as adverse consequences of aging, wrinkling, altered pigmentation, altered viscoelasticity, and altered thickness, among others. Methods for using the compositions and topical formulations for treating adverse or undesirable dermatological conditions are also provided, as well as preventing the appearance of undesirable dermatological conditions. | 2013-04-18 |
20130095062 | RECOMBINANT PRODUCTION OF AUTHENTIC HUMAN PROTEINS USING HUMAN CELL EXPRESSION SYSTEMS - The present invention relates to novel expression cassettes and vectors for efficiently producing authentic recombinant human proteins from stable cultures of novel human cell lines, the authentic recombinant proteins produced therefrom, and antibodies raised against those authentic recombinant proteins. | 2013-04-18 |
20130095063 | Compounds for the Treatment of Hepatitis C - The disclosure provides compounds of formula I, including pharmaceutically acceptable salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV. | 2013-04-18 |
20130095064 | SUBSTITUTED 3',5'-CYCLIC PHOSPHATES OF PURINE NUCLEOTIDE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS - Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents | 2013-04-18 |
20130095065 | Methods for Treating Vascular Leak Syndrome and Cancer - Disclosed are methods for treating Vascular Leak Syndrome and preventing cancer metastasis. Further disclosed are methods for treating vascular leakage due to inflammatory diseases, sepsis, cancer or the presence of pathogens. | 2013-04-18 |
20130095066 | Compounds for the Treatment of Hepatitis C - The disclosure provides compounds of formula I, including pharmaceutically acceptable salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV. | 2013-04-18 |
20130095067 | LYSINE DEMETHYLASE INHIBITORS FOR DISEASES AND DISORDERS ASSOCIATED WITH HEPADNAVIRIDAE - The present invention provides for the treatment or prevention of Hepadnaviridae infection and disease caused by Hepadnaviridae infection. In particular, the invention provides compositions and methods that affect the ability of Hepadnaviridae to utilize the host's cellular machinery as part of the virus' lifecycle. The invention relates to the discovery that interfering with the normal ability of viruses to utilize the host cell machinery with LSD1 inhibitors reduces HBV replication. Thus, the treatment and prevention of Hepadnaviridae infection and disease caused by Hepadnaviridae according to the invention comprises administering to an individual in need of treatment, a therapeutically effective amount of a LSD1 inhibitor. The individual in need of treatment can be a human or, e.g., another mammal. | 2013-04-18 |
20130095068 | AGENT FOR TREATING HCV INFECTION - Provided is an imidazolylbenzene compound or salt thereof that controls HCV replication and in addition is particularly capable of strongly controlling HCV replication, and is very effective in the prevention and treatment of HCV infection when used in combination with another agent for treating HCV infection such as Interferon. | 2013-04-18 |
20130095069 | METHOD OF TREATING AUTOIMMUNE DISEASES WITH INTERFERON-BETA AND IL-2R ANTAGONIST - Disclosed is a method of administering an interleukin-2 receptor (IL-2R) antagonist to a subject to treat an autoimmune disease. In particular embodiments, the IL-2R antagonist is an anti-IL-2R monoclonal antibody specific for one or more chains of the IL-2R, such as the alpha-chain, for example daclizumab. In other particular embodiments the autoimmune disease is multiple sclerosis. In certain embodiments administration of interferon-beta is combined with administration of an antagonist of the IL-2R to provide significant clinical improvement in a subject with an autoimmune disease. | 2013-04-18 |
20130095070 | USE OF CHICORIC ACID AND DERIVATIVES FOR REGULATING SKIN PIGMENTATION - The present invention relates generally to the field of food supplements for cosmetic purpose. More specifically, the present invention aims to provide an ingredient containing chicoric acid and/or derivatives for preventing and/or treating hyper-pigmentation of skin, skin color imperfections such as age-spots and other skin disorders characterized by abnormal pigments. The present invention also aims at improving skin tone as well as providing a skin lightening agent. | 2013-04-18 |
20130095071 | METHOD OF TREATING OR PREVENTING HEARING LOSS - Disclosed herein is a method of delivering a mutated tyrosine adeno-associated viral vector or a pharmaceutically active agent to an inner ear. The method comprises contacting the round window membrane with the vector or the pharmaceutically active agent, in which the permeability of the round window membrane having been enhanced to allow transport of the vector or the pharmaceutically active agent across it so as to deliver the vector or the pharmaceutically active agent to the inner ear. Also disclosed are methods to prevent or treat hearing loss and impaired balance in human subjects using the delivery method. | 2013-04-18 |
20130095072 | THERAPEUTIC AGENT FOR ISCHEMIC DISEASES | 2013-04-18 |
20130095073 | SKIN PROPERTIES IMPROVING AGENT FOR ORAL ADMINISTRATION - Disclosed is a skin property-improving agent which exerts excellent effects by oral administration. The skin property-improving agent for oral administration contains, as an active ingredient, a bacterium belonging to the genus | 2013-04-18 |
20130095074 | USE OF CAFTARIC ACID AND LACTIC BACTERIUM IN FOOD SUPPLEMENT FOR REGULATING SKIN PIGMENTATION - The present invention relates generally to the field of cosmetic and/or food supplement. More specifically, the present invention aims to provide the use of at least an ingredient containing caftaric acid and/or derivatives and a micro-organism and/or an enzyme capable of hydrolyzing caftaric acid and/or derivatives thereof to generate tartaric and/or caffeic acid, for improving skin tone and preventing and/or treating hyper-pigmentation of skin and/or skin color imperfections such as age-spots and other skin disorders characterized by abnormal pigments. Also, the present invention aims at providing a skin lightening agent. | 2013-04-18 |
20130095075 | BONE MORPHOGENIC PROTEIN BINDING PEPTIDE - A cyclized peptide designated BMP Binding Peptide (BBP) is a synthetic peptide that avidly binds rhBMP-2. BBP increases the overall osteogenic activity of rhBMP-2, increases the rate at which rhBMP-2 induces bone formation, and BBP induces calcification alone. Compositions and substrates including BBP, and methods of using BBP are useful in therapeutic, diagnostic and clinical applications requiring calcification and osteogenesis. | 2013-04-18 |
20130095076 | Methods For Increasing Blood Flow And/Or Promoting Tissue Regeneration - Methods for increasing blood flow and/or regenerating tissue using compounds which bind to the chemokine receptor CXCR4 are disclosed. Preferred embodiments of such compounds are of the formula | 2013-04-18 |
20130095077 | Somatic Stem Cells - A somatic stem cell that is CD10+, CXCR4+, and CD31+ and another somatic stem cell that is CD 105+, CD44+, and nestin+. Also disclosed are both a method of preparing these stem cells and a method of using them to treat degenerative diseases, e.g., a muscle-degenerative disease. The invention further includes making and using liver cells derived from the somatic cell that is CD105+, CD44+, and nestin+. | 2013-04-18 |
20130095078 | METHODS FOR REGENERATING SKELETAL MUSCLE - An engineered muscle construct in the form of a braided collagen microthread scaffold is provided. The microthread scaffold can be used with or without cells as engineered skeletal muscle. The microthread scaffold can also be used to promote cell attachment and growth to deliver cells to a large muscle defect to stimulate muscle regeneration. Methods for making a muscle construct, seeding cells onto microthread scaffolds and treating muscle defects are also provided. | 2013-04-18 |
20130095079 | COMPOSITIONS AND METHODS FOR PROVIDING HEMATOPOIETIC FUNCTION WITHOUT HLA MATCHING - The present invention relates to methods and compositions for providing hematopoietic function in immunodeficient human patients, by selecting an expanded human umbilical cord blood stem/progenitor cell sample without taking into account the HLA-type of the expanded human cord blood stem/progenitor sample or the HLA-type of the patient; and administering the selected expanded human cord blood stem/progenitor cell sample to the patient. Methods for obtaining the expanded human cord blood stem/progenitor cell samples, banks of frozen expanded human cord blood stem/progenitor cell samples, and methods for producing such banks are also provided herein. | 2013-04-18 |
20130095080 | COMPOSITIONS AND METHODS FOR PROVIDING HEMATOPOIETIC FUNCTION - The present invention relates to methods and compositions for providing hematopoietic function to human patients in need thereof, by selecting a pool of expanded human cord blood stem/progenitor cell samples for administration to the patient, wherein the samples in the pool collectively do not mismatch the patient at more than 2 of the HLA antigens or alleles typed in the patient; and administering the selected pool of expanded human cord blood stem/progenitor cell samples to the patient. Methods for obtaining the pools of expanded human cord blood stem/pro-genitor cell samples, banks of frozen pools of expanded human umbilical cord blood stem/progenitor cell samples, and methods for producing such banks are also provided herein. | 2013-04-18 |
20130095081 | COMPOSITIONS AND METHODS OF TREATMENT WITH STEM CELLS - The disclosure of the present application provides compositions and methods of treatment with stem cells. In at least one embodiment of a method for treating a patient with an insulin-related disorder, the method comprises the step of administering a cell-based composition to a patient with an insulin-related disorder to treat the insulin-related disorder, the cell-based composition comprising at least one mammalian stem cell and optionally at least one islet cell, the at least one mammalian stem cell capable of prolonging an effective life of the at least one islet cell. | 2013-04-18 |
20130095082 | USE OF DES-ASPARTATE-ANGIOTENSIN I IN INFLAMMATION-RELATED PATHOLOGIES AND DISEASES - The present disclosure generally relates to the use of des-aspartate-angiotensin I and/or its derivatives in medicine. In particular, the present invention relates to the use of des-aspartate-angiotensin I and/or its derivatives for the treatment and/or prophylaxis of inflammatory diseases or pathologies, for inducing anti-inflammatory actions and/or reducing inflammation, and/or for treatment of inflammation-related conditions. | 2013-04-18 |
20130095083 | Method For Controlling And Accelerating Differentiation Of Stem Cells Using Graphene Substrates - The invention relates to methods for directing differentiation of stem cells comprising graphene. In additional embodiments, the invention relates to methods for repairing and improving bone tissue functions comprising accelerating differentiation in stem cell growth by exposing stem cells to graphene and transplanting the graphene with the exposed stem cells in the tissue at the site of repair. | 2013-04-18 |
20130095084 | METHODS AND COMPOSITIONS FOR MODULATING PERIPHERAL IMMUNE FUNCTION - Disclosed herein are cell preparations useful for modulating various peripheral immune functions, methods for making said cell preparations, and methods for their use. | 2013-04-18 |
20130095085 | METHOD FOR PRODUCING HEMATOPOIETIC STEM CELLS - An expanding agent for hematopoietic stem cells and/or hematopoietic progenitor cells useful as a therapy for various hematopoietic diseases and useful for improvement in the efficiency of gene transfer into hematopoietic stem cells for gene therapy is provided. | 2013-04-18 |
20130095086 | COMPOSITION AND USE OF LACTOBACILLUS PARACASEI STRAIN GMNL-133 IN TREATING ATOPIC DERMATITIS OR OTHER ALLERGIC DISEASES - An isolated | 2013-04-18 |
20130095087 | ABSORBABLE IN SITU GEL-FORMING SYSTEM, METHOD OF MAKING AND USE THEREOF - An in situ gel-forming composition is disclosed. The in situ gel-forming composition comprises one or more absorbable polymers, solvents such as N-methyl-2-pyrrolidone, polyethylene glycol or DMSO, and optionally one or more bioactive agent. The composition forms a hydrogel or semi-solid mass on contact with an aqueous environment. The method of using in situ gel-forming composition for various applications is also disclosed. | 2013-04-18 |
20130095088 | Topical skin care formulations - A topical anti-aging skin care formulation comprising an effective amount of a benzoquinone, such as CoQ10, plus a synergistic pair of stabilizers and a synergistic pair of whiteners. The stabilizers are octyl salicylate and octyl methoxycinnamate. The whiteners are titanium dioxide and zinc oxide. When proper amounts of these ingredients are used in an aqueous based emulsion formulation, the product will be initially white, and will remain white for an extended period of time. | 2013-04-18 |
20130095089 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS AND THERAPEUTIC METHODS USING THE SAME - Glucosylceramide synthase inhibitors and compositions containing the same are disclosed. Methods of using the glucosylceramide synthase inhibitors in the treatment of diseases and conditions wherein inhibition of glucosylceramide synthase provides a benefit, like Gaucher disease and Fabry disease, also are disclosed. | 2013-04-18 |
20130095090 | FACTOR VIIA COMPLEX USING AN IMMUNOGLOBULIN FRAGMENT - Disclosed are a blood coagulation factor complex in which FacVIIa, a non-peptidyl polymer and an immunoglobulin Fc region are bonded by covalent bonds, and the uses thereof. The FacVIIa complex guarantees the in vivo activity of FacVIIa and significantly enhances the serum half life of FacVIIa, so that it is useful for developing long-acting FacVIIa formulations which can improve the compliance of role behavior of patients whose blood does not coagulate. | 2013-04-18 |
20130095091 | METHODS OF REGULATING UPTAKE AND TRANSCELLULAR TRANSPORT OF LEUKOCYTES AND THERAPEUTICS - Methods for controlling and regulating engulfment, uptake and/or transcellular transport at a stage following initial engagement of an agent to the endothelium are provided, based on the identification of CAM-mediated endocytosis and the sphingomyelin/ceramide pathway as active steps in transcellular TEM. Administration of regulators relating to the identified pathways, such as NHE1, sphingomyelinases, acid sphingomyelinase and ceramide, permit control and regulation of uptake and transcellular transport. Control and regulation of uptake and/or transcellular transport is applicable in strategies to modulate inflammation, provide controlled and/or targeted delivery of agents, control pathogenic invasion, recover action of an inhibited CAM-mediated uptake or transendothelial pathway, or provide uptake or transendothelial transport by targeting cell surface markers other than ICAM-1. | 2013-04-18 |
20130095092 | RECOMBINANT HUMAN NAGLU PROTEIN AND USES THEREOF - The present invention provides compositions comprising an isolated mixture of recombinant human NaGlu proteins in which a substantial amount of the NaGlu proteins in the mixture has increased levels of phosphorylated mannose that confer the proteins to be efficiently internalized into human cells. The present invention also provides methods of producing such mixture of NaGlu proteins, vectors used in transgenesis and expression, host cells harboring such vectors, and methods of isolating and purifying the mixture of NaGlu proteins. The invention further provides methods of treating NaGlu associated diseases. | 2013-04-18 |
20130095093 | METHODS AND COMPOSITIONS FOR TREATMENT OF IMMUNE DYSFUNCTION DISORDERS - Methods and compositions are disclosed for modulating the immune system of animals. Applicant has identified that oral administration of immunoglubulin or plasma fractions purified from animal serum can modulate serum IgG and/or TNF-α levels for treatment of autoimmune disorders, potentiation of vaccination protocols, and improvement of overall health and weight gain in animals, including humans. | 2013-04-18 |
20130095094 | ASSAY - The invention provides assays and apparatuses for assessing the ability of certain orally-ingestible samples, such as saliva or foodstuffs to cause inflammation, and thus the health risk such samples can cause upon ingestion by a subject. The invention also provides an assay to monitor an individual's diet with regards to inflammation risk. The invention also extends to methods of preventing inflammatory diseases. | 2013-04-18 |
20130095095 | METHOD FOR TREATING THROMBOTIC DISORDERS USING QUERCETIN-CONTAINING COMPOSITIONS - A method for treating thrombotic disorders using a composition containing quercetin, together with one or more of vitamin B | 2013-04-18 |
20130095096 | NOVEL ANTI- ALPHA5BETA1 ANTIBODIES AND USES THEREOF - The present invention provides new anti-α5β1 antibodies, compositions and kits comprising the antibodies, and methods of making and using the antibodies. | 2013-04-18 |
20130095097 | Polypeptide Heterodimers and Uses Thereof - The present disclosure provides polypeptide heterodimers formed between two different single chain fusion polypeptides via natural heterodimerization of an immunoglobulin CH1 region and an immunoglobulin light chain constant region (CL). One chain of a heterodimer comprises a binding domain that specifically binds a target (e.g., a receptor). In addition, both chains of a heterodimer further comprise an Fc region portion. The present disclosure also provides nucleic acids, vectors, host cells and methods for making polypeptide heterodimers as well as methods for using such polypeptide heterodimers, such as in reducing T cell activation, inhibiting solid malignancy growth, and treating autoimmune or inflammatory conditions. | 2013-04-18 |
20130095098 | PD-1 ANTIBODY - A humanised agonistic antibody which binds human PD-1 comprising a heavy chain wherein the variable domain of the heavy chain comprises the sequence given in SEQ ID NO:1 for CDR-H1, the sequence given in SEQ ID NO: 2 for CDR-H2 and the sequence given in SEQ ID NO: 3 for CDR-H3 and the heavy chain framework region is derived from human sub-group sequence VH4 3-1 4-30.4+JH4 (SEQ ID NO: 33). The disclosure also extends to therapeutic uses of the antibody molecules, compositions and methods for producing said antibody molecules. | 2013-04-18 |
20130095099 | GENES AND GENES COMBINATIONS PREDICTIVE OF EARLY RESPONSE OR NON RESPONSE OF SUBJECTS SUFFERING FROM INFLAMMATORY DISEASE TO CYTOKINE TARGETING DRUGS (CYTD) - The invention concerns methods for the in vitro diagnosis/prognosis of a CyTD responsive or non-responsive phenotype, comprising: (a) determining from a subject biological sample an expression profile comprising the gene MAPK14; or the genes MAPK14 and S100A9; or the genes MAPK14 and GNLY; or the 6 genes of Table 2, or the gene S100A9; or the genes S100A9, IL2RB, and CASP5; or the genes S100A9, IL2RB, KLRK1, HCK, and GNLY; or the genes S100A9, IL2RB, KLRK1, HCK, GNLY, CTSZ, ARF5, and UTP14C, or Equivalent Expression Profile of anyone of the expression profiles of (i) and (ii), and optionally one or more housekeeping gene(s), (b) comparing the obtained expression profile with at least one reference expression profile, and (c) determining the responsive or non-responsive phenotype from said comparison. The present invention also relates to kits and nucleic acid microarrays for performing said method, and methods of treatment of inflammatory disease-suffering patients. | 2013-04-18 |
20130095100 | HETEROCYCLIC KINASE INHIBITORS - This invention relates to novel 2-{6-[4-(2-hydroxy-ethyl)-piperazin-1-yl]-2-methyl-pyrimidin-4-ylamino}-thiazole-5-carboxylic acid (2-chloro-6-methyl-phenyl)-amide derivatives, and pharmaceutically acceptable acid addition salts thereof. The invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions beneficially treated by the inhibition of kinases including Src-kinase and Bcr-Abl kinase. | 2013-04-18 |
20130095101 | METHODS AND COMPOSITIONS FOR TREATMENT AND DIAGNOSIS OF FIBROSIS, TUMOR INVASION, ANGIOGENESIS, AND METASTASIS - Provided are methodology, compositions and kits to prevent and treat diseases associated with abnormal cell proliferation, angiogenesis and fibrosis, using processed lysyl oxidase or lysyl oxidase-like protein inhibitors, LOX inhibitors and LOXL inhibitors, or synergistic combinations of such inhibitors with therapeutic agents. Provided are methods for selecting tumor invasion, angiogenesis and metastasis inhibiting agents, by contacting cells in EMT states with candidate agents and detecting changes in such states; and methods, compositions, and kits for diagnosing or monitoring diseases associated with abnormal cell proliferation, angiogenesis and fibrosis, using molecules or agents specifically recognizing processed LOX or LOXL. Provided are methods, compositions, medical devices, systems and kits for preventing or treating diseases and conditions associated with fibrosis, including pathological cardiovascular conditions and diseases, e.g., hypertension, hypertensive heart disease, myocardial infarction, atherosclerosis, restenosis, liver fibrosis, kidney fibrosis, lung fibrosis, dermal scaring, keloid formation, and Alzheimer's disease, with LOX or LOXL inhibitors. | 2013-04-18 |
20130095102 | DIMERIC FUSION PROTEINS AND RELATED COMPOSITIONS AND METHODS - Compositions and methods relating to soluble dimeric proteins are disclosed. The dimeric proteins comprise first and second polypeptide fusions linked via a dimerizing domain, each polypeptide fusion comprising first and second monomer domains corresponding to a cytokine or an extracellular domain of a cell-surface receptor. The monomer domains may be positioned amino terminal and carboxyl terminal to the dimerizing domain. Alternatively, the monomer domains may be positioned in tandem, either carboxyl terminal or amino terminal to the dimerizing domain. The dimeric proteins are useful in methods for therapy, diagnosis, and research. | 2013-04-18 |
20130095103 | MEANS AND METHODS FOR THE TREAMENT OF TUMOROUS DISEASES - Provided are pharmaceutical means and methods for the prevention, treatment or amelioration of indolent or aggressive B cell non-Hodgkin lymphoma (B NHL) and B cell leukemia comprising the administration of a bispecific single chain antibody construct to a subject in the need thereof and the use of said bispecific single chain antibody construct for the preparation of a pharmaceutical composition for the prevention, treatment or amelioration of indolent or aggressive B cell non-Hodgkin lymphoma (B NHL) and B cell leukemia, whereby said construct is to be administered for at least 1 week in specified daily doses. Moreover, the invention relates to kits comprising a bispecific single chain antibody construct to be used in accordance with this invention. | 2013-04-18 |
20130095104 | ANTI-FZD10 MONOCLONAL ANTIBODIES AND METHODS FOR THEIR USE - The present invention relates generally to anti-FZD10 antibodies and to methods of using anti-FZD10 antibodies. In particular, the anti-FZD10 antibodies described herein are useful for altering one or more of survival, replication, differentiation and epithelial-to-mesenchymal cell transition of embryonic stem cells and/or for the treatment of diseases, such as a variety of cancers, associated with expression of FZD10, including as stand-alone therapies and in combination therapies with other agents. | 2013-04-18 |
20130095105 | Treatment of Ocular Disease - Disclosed are methods for treating eye diseases or conditions characterized by vascular instability, vascular leakage and neovacularization such as diabetic macular edema, age-related macular edema, choroidal neovascularization, diabetic retinopathy, trauma, ocular ischemia, retinal angiomatous proliferation, macular telangiectasia and uveitis. | 2013-04-18 |
20130095106 | USE OF TRIFUNCTIONAL BISPECIFIC AND TRISPECIFIC ANTIBODIES FOR THE TREATMENT OF MALIGNANT ASCITES - The invention describes the use of a pharmaceutical preparation containing a trifunctional bispecific and/or trispecific having the following properties:
| 2013-04-18 |
20130095107 | BIOMARKER SPECIFIC TO BRAIN/NERVE OR SPECIFIC TO NEURONAL DIFFERENTIATION - The invention provides a novel polypeptide and a specific partial peptide thereof, as well as a novel polynucleotide and a specific partial nucleotide thereof, that can be used as a biomarker specific for the brain/nerves or specific for nerve differentiation; an expression vector for such a polynucleotide and a specific partial peptide thereof; a transformant incorporating such an expression vector; an antisense molecule, RNAi-inducing nucleic acid (e.g., siRNA), aptamer, or antibody for such a biomarker, and a composition comprising the same; a mammalian cell or non-human mammal wherein the expression or a function of such a biomarker is regulated; a measuring means (e.g., primer set, nucleic acid probe, antibody, aptamer) for such a biomarker, and a reagent comprising the same and the like. | 2013-04-18 |
20130095108 | FACTOR XII INHIBITORS FOR TREATING INTERSTITIAL LUNG DISEASE - The present invention provides methods for treating interstitial lung diseases, comprising administering to an individual an effective amount of an inhibitor of coagulation factor XII. The invention further provides uses and pharmaceutical kits for that treatment. | 2013-04-18 |
20130095109 | ANTIBODY POLYPEPTIDES THAT ANTAGONIZE CD40L - Antibody polypeptides that specifically bind human CD40L are provided. The antibody polypeptides do not activate platelets. The antibody polypeptides are useful in the treatment of diseases involving CD40L activation, such as graft-related diseases and autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single V | 2013-04-18 |
20130095110 | Hyaluronic Acid Decomposition-Promoting Factor and Inhibitor Thereof - The present invention is directed to KIAA1199, which is a novel factor involved in decomposition of hyaluronic acid, and to use thereof. More specifically, the invention is directed to a hyaluronic acid decomposition-promoting agent containing the KIAA1199 gene and a protein encoded by the gene; to a hyaluronic acid decomposition-inhibiting agent characterized by inhibiting the activity or expression thereof (including an siRNA or a monoclonal antibody); and to a method for screening a novel hyaluronic acid decomposition-controlling agent, in which the method contains employing the expression of KIAA1199 as an index. | 2013-04-18 |
20130095111 | FUSION PROTEINS IN CANCER - The present invention provides fusion proteins expressed by cancer cells, antibodies and other antigen-binding agents that specifically bind to the fusion proteins, and compositions and methods for using the antibodies and other antigen-binding agents to detect, characterize, and treat cancer. | 2013-04-18 |
20130095112 | NOVEL METHODS FOR TREATING EGFR-ASSOCIATED TUMORS - The invention relates to a method for the treatment of an EGFR-associated tumor comprising administration, to an individual in need thereof, of an anti-EGFR antibody in combination with radiotherapy and a radiosensitising agent. In one embodiment, the treatment further comprises administration of a chemotherapeutic agent. | 2013-04-18 |
20130095113 | COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL DISORDERS - The present disclosure provides methods for treating neurological disorders, generally involving modulating protein kinase D1 (PKD1) activity levels in a neuron or glial cell in an individual in need thereof. The present disclosure provides antibodies specific for PKD1. The present disclosure provides a genetically modified non-human mammal deficient in PKD1 activity. | 2013-04-18 |
20130095114 | T Cell Regulation - Combinations of anti-cancer vaccines and inhibitory antibodies to CD223 overcome immune suppression in cancer patients. The vaccines may be isolated antigens, groups of antigens, or whole tumor cells. The inhibitory antibodies may be generated in an animal by injection of fragments of CD223. Antibodies may be monoclonal antibodies or single chain antibodies or humanized antibodies. | 2013-04-18 |
20130095115 | STAPHYLOCOCCUS AUREUS LEUKOCIDINS, THERAPEUTIC COMPOSITIONS, AND USES THEREOF - Disclosed herein are isolated and purified | 2013-04-18 |
20130095116 | RSPO Binding Agents and Uses Thereof - The present invention relates to RSPO-binding agents and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human RSPO proteins and modulate β-catenin activity. The present invention further provides methods of using agents that modulate the activity of RSPO proteins, such as antibodies that specifically bind RSPO1, RSPO2, and/or RSPO3 and inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer. | 2013-04-18 |
20130095117 | THERAPEUTIC USES OF INHIBITORS OF RTP801 - The present invention provides novel molecules, compositions, methods and uses for treating microvascular disorders, eye diseases and respiratory conditions based upon inhibition of the RTP801 gene and/or protein. | 2013-04-18 |
20130095118 | Use of Semaphorin-4D Binding Molecules for Modulation of Blood Brain Barrier Permeability - Provided herein are methods for decreasing blood-brain barrier permeability in a subject with a neuroinflammatory disorder, comprising administering to the subject an effective amount of an isolated binding molecule which specifically binds to semaphorin-4D (SEMA4D) or to its high affinity Plexin-B1 receptor. | 2013-04-18 |
20130095119 | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AN INFLAMMATION - A method of reducing an inflammatory response in a subject is provided. The method comprising providing to a subject in need thereof a therapeutically effective amount of an agent capable of reducing activity and/or expression of a scavenger receptor or of an effector thereof, thereby reducing the inflammatory response in the subject. | 2013-04-18 |
20130095120 | ANTI-PLATELET MEMBRANE GLYCOPROTEIN VI MONOCLONAL ANTIBODY - The present invention provides an antibody which has the following features, its active fragment, or a derivative thereof: a) It specifically binds to human platelet membrane glycoprotein VI (GPVI); b) The function to activate a platelet and/or the function to induce a thrombocytopenia in vivo are low; and c) It at least partially depletes GPVI on the platelet membrane by contacting with a platelet. | 2013-04-18 |
20130095121 | METHODS OF TREATING PATIENTS WITH IMMUNE-RELATED DISEASES - Provided herein are methods of treating patients with immune-related diseases (e.g., diabetes) with immunotherapy. | 2013-04-18 |
20130095122 | Peptides or Antibodies Which Bind to Melanoma Inhibitory Activity (MIA) Protein - The present invention relates to peptides and antibodies which bind to melanoma inhibitory activity protein and the uses of such peptides and antibodies. The invention also relates to nucleic acids coding for such peptides or antibodies. The invention also relates to pharmaceutical compositions comprising such peptides or antibodies or such nucleic acids. The present invention also relates to small molecule compounds which bind to melanoma inhibitory activity protein and to uses of such small molecule compounds. Moreover, the present invention also relates to a method of preventing dimerization and/or aggregation of melanoma inhibitory activity (MIA) protein. The invention is based on the identification of the relevant sites of interaction of the MIA protein with the inhibitory peptides/antibodies. Considering the amino acid sequence of this protein deprived from the signalling peptide, the residues involved in the interaction are selected from: A7, K53, G54, R55, R57, L58, F59, V64, Y69, R85, D87, K91, and more preferably C17, S18, Y47, G61, G66, D67, L76, W102, D103, C106. | 2013-04-18 |
20130095123 | New binder-drug conjugates (ADCs) and use thereof - The present application relates to new binder-drug conjugates (ADCs) of N,N-dialkylauristatins that are directed against the target C4.4a, to active metabolites of these ADCs, to processes for preparing these ADCs, to the use of these ADCs for treating and/or preventing illnesses, and also to the use of these ADCs for producing medicaments for treating and/or preventing illnesses, more particularly hyperproliferative and/or angiogenic diseases such as, for example, cancer diseases. Such treatments may be practised as a monotherapy or else in combination with other medicaments or further therapeutic measures. | 2013-04-18 |
20130095124 | COMPOSITIONS FOR TRANSFECTION OF BIOMOLECULES INTO CELLS - The present invention is directed to new compositions that are described for the simultaneous, controlled dose delivery of a variety of biomolecules into phagocytic cells. Such a composition is a biologically active composition comprising: (1) at least one of the following biologically active components: (a) a nucleic acid or a derivative thereof; (b) a nucleoside, nucleotide, or a derivative of a nucleoside or nucleotide; (c) a peptide, protein, or a derivative of a peptide or protein; (d) a lipopolysaccharide or a derivative thereof; (e) a peptidoglycan or a derivative thereof; (f) a carbohydrate or a derivative thereof; (g) a lipid or a derivative thereof; (h) a lipopeptide or a derivative thereof; (i) a metal ion; (j) a thiol; (k) an antibiotic or a derivative thereof; (I) a vitamin or a derivative thereof; (m) a bioflavonoid or a derivative thereof; (n) an antioxidant or a derivative thereof; (o) an immune response modifier; (p) an antibody; (q) a biologically active nonmetal; (r) histamine or an antihistamine; and (s) a kinase inhibitor; and (2) at least one carrier effective to deliver the composition to a phagocytic cell such that the biologically active component is taken up by the phagocytic cell and influences its biological activity. | 2013-04-18 |
20130095125 | PALATINOSE FOR ENHANCING DIETARY SUPPLEMENT AND PHARMACEUTICAL DELIVERY - The present invention is directed to a dietary supplement comprising palatinose or a derivative thereof. The dietary supplement may be a nutritional product, a sports performance product, a weight loss product or a meal replacement product. The present invention is also directed to a method of increasing the absorption of a compound into the bloodstream, cells and tissue comprising administering palatinose, or a derivative thereof, in combination with the compound. | 2013-04-18 |
20130095126 | USE OF SUBSTITUTED HETEROCYCLIC COMPOUNDS TO CONTROL SEA LICE ON FISH - The present invention relates to the use of compounds of formula | 2013-04-18 |
20130095127 | METHODS OF INHIBITING INFLAMMATION AND INFLAMMATORY DISEASES USING Gal-3BP (BTBD17B, LGALS3BP, GALECTIN-3 BINDING PROTEIN, MAC-2 BINDING PROTEIN) - The invention provides Galectin-3 binding protein (Gal-3BP, BTBD17B) polypeptides, Gal-3BP compositions, and methods of use, and uses, for example, in treatment, diagnostic, detection and prognostic methods, such as treatment of an undesirable or aberrant immune response, immune disorder, inflammatory response, or inflammation, and treatment of an autoimmune response, disorder or disease. | 2013-04-18 |
20130095128 | ECT2 PEPTIDES AND VACCINES INCLUDING THE SAME - Isolated peptides derived from SEQ ID NO: 42 and fragments thereof that bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL) and thus are suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines, are described herein. The inventive peptides encompass both the afore-mentioned amino acid sequences and modified versions thereof, in which one, two, or several amino acids are substituted, deleted, inserted or added, provided such modified versions retain the requisite HLA binding and/or CTL inducibility of the original sequences. Further provided are nucleic acids encoding any of the aforementioned peptides as well as pharmaceutical agents, substances and/or compositions that include or incorporate any of the aforementioned peptides or nucleic acids. The peptides, nucleic acids, pharmaceutical agents, substances and compositions of this invention find particular utility in the treatment of cancers and tumors, including, for example, bladder cancer, breast cancer, cervical cancer, cholangiocellular carcinoma, CML, colorectal cancer, esophageal cancer, NSCLC, lymphoma, pancreatic cancer, prostate cancer, renal carcinoma and SCLC. | 2013-04-18 |
20130095129 | TREATMENT OF IMMUNE DISEASE BY MUCOSAL DELIVERY OF ANTIGENS USING GENETICALLY MODIFIED LACTOBACILLUS - The present invention relates to the treatment of autoimmune and allergic diseases by mucosal delivery by micro-organism, in particular | 2013-04-18 |
20130095130 | Methods and Compositions for Providing Protective Immunity in the Elderly - Compositions that include a flagellin/antigen protein comprising at least a portion of at least one flagellin and at least a portion of at least one antigen and methods of administering these compositions to humans at least 49 years old. The compositions stimulate immune response to the antigen, in particular, a protective immune response to the antigen, in the human, such as an elderly human. | 2013-04-18 |
20130095131 | Vaccine and Therapeutic Delivery System - The present invention relates to a new vaccine delivery system. In particular, the present invention includes compositions and methods of integrally transformed non-pathogenic, commensal bacteria that can express a nucleic acid molecule of a foreign polypeptide, wherein the nucleic acid molecule that encodes the foreign polypeptide is stably integrated into genomic DNA of the bacteria. The foreign polypeptide includes a vaccine antigen that elicits an immunogenic response, an inhibitor of a pathogen, or an immune booster or modulator. | 2013-04-18 |
20130095132 | TUBERCULOSIS VACCINES COMPRISING ANTIGENS EXPRESSED DURING THE LATENT INFECTION PHASE - The invention is related to an immunogenic composition, vaccine or pharmaceutical composition for preventing, boosting or treating infection caused by a species of the tuberculosis complex ( | 2013-04-18 |
20130095133 | PHARMACEUTICAL COMPOSITIONS COMPRISING A POLYPEPTIDE COMPRISING AT LEAST ONE CXXC MOTIF AND HETEROLOGOUS ANTIGENS AND USES THEREOF - The invention relates to pharmaceutical compositions using a polypeptide comprising at least one CXXC motif, such as | 2013-04-18 |
20130095134 | STABILIZED VIRUS LIKE PARTICLES HAVING ENHANCED MUCOSAL IMMUNOGENICITY - This disclosure relates to compositions and methods for inducing immune response. Specifically, the disclosure relates to a composition comprising a subunit antigen stabilized by a polysaccharide-containing plant extract, in which the antigen consists of virus-like particles that have enhanced mucosal immuno-genicity as a result of the stabilization. | 2013-04-18 |
20130095135 | PROCESS FOR REMOVING ADVENTITIOUS AGENTS DURING THE PRODUCTION OF A VIRUS IN CELL CULTURE - The present invention relates to improved processes for the production of viruses, in particular, viruses for use in medicine (for example vaccination or gene therapy). | 2013-04-18 |
20130095136 | Tetravalent Dengue Vaccines - The invention provides tetravalent Dengue vaccines, and methods of using these vaccines to prevent or to treat Dengue infection. | 2013-04-18 |
20130095137 | PAN-LYSSAVIRUS VACCINES AGAINST RABIES - Described herein are recombinant rabies viruses encoding rabies virus glycoprotein and at least one heterologous glycoprotein from another | 2013-04-18 |
20130095138 | Method and Apparatus for Producing a Stabilized Antimicrobial Non-toxic Electrolyzed Saline Solution Exhibiting Potential as a Therapeutic - An improved method and apparatus for producing a stable, non-toxic, antimicrobial electrolyzed saline solution with a broad range of anti-infective and therapeutic applications. The resulting electrolyzed saline solution exhibits a marked lack of toxicity upon intravenous, aspired, oral or topical application in mammals for therapeutic applications providing a broad platform, including topical disinfection, antimicrobial application, wound treatment, oxidative stress reduction and enhancement of immune function to better detect malfunctioning cells. | 2013-04-18 |
20130095139 | BONE MORPHOGENIC PROTEIN BINDING PEPTIDE - A cyclized peptide designated BMP Binding Peptide (BBP) is a synthetic peptide that avidly binds rhBMP-2, as do endogenous forms of BBP, and sequence conservation between species results in a variety of useful BBP compositions. BBP increases the over-all osteogenic activity of rhBMP-2, increases the rate at which rhBMP-2 induces bone formation, and BBP induces calcification alone. Compositions and substrates including BBP, and methods of using BBP are useful in therapeutic, diagnostic and clinical applications requiring calcification and osteogenesis. | 2013-04-18 |
20130095140 | Biguanide Compositions and Methods of Treating Metabolic Disorders - Provided herein are methods for treating certain conditions, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administrating a composition comprising a biguanide or related heterocyclic compound, e.g., metformin. Also provided herein are biguanide or related heterocyclic compound compositions, and methods for the preparation thereof for use in the methods of the present invention. Also provided herein are compositions comprising metformin and salts thereof and methods of use. | 2013-04-18 |
20130095141 | FOOD GRADE DRY FILM COATING COMPOSITION AND METHODS OF MAKING AND USING THE SAME - A dry film coating composition comprising a cellulose film former, an oligofructose fiber, a plasticizing agent, and a processing aid is disclosed herein. Also provided is a film coating suspension comprising a cellulose film former, an oligofructose fiber, a plasticizing agent, a processing aid, and a solvent. The film coating suspension may be applied to a substrate, such as, for example, nutritional supplements, pharmaceuticals, tablets, capsules, softgels, granules, particles (e.g., micro- and nano-particles), agricultural seeds, and the like to form a dry film coating on the substrate. Methods of coating a substrate with the film coating suspensions are also provided. | 2013-04-18 |
20130095142 | Lipid Emulsion Having Krill Oil As An Active Ingredient And Preparation Method Therefor - Provided is a lipid emulsion having krill oil as an active ingredient and a preparation method therefor, wherein the lipid emulsion can be used independently for oral/parenteral administration or as a daily nutrient, and preferably, as a nutritious intravenous lipid emulsion having krill oil. | 2013-04-18 |
20130095143 | BIOMATERIAL FROM WHARTON'S JELLY UMBILICAL CORD - The present invention relates to a biomaterial, specifically a hydrogel, based on the extracellular matrix of the umbilical cord for its application in regenerative medicine. The invention particularly relates to a biomaterial made up of glycosaminoglycans present exclusively in the Wharton's jelly of the umbilical cord (which can optionally be combined with cells as a combination therapy), and also to the methods for the production and use thereof. | 2013-04-18 |
20130095144 | PHARMACEUTICAL COMPOSITIONS OF SIROLIMUS - The present invention discloses a stable solid pharmaceutical matrix composition comprising sirolimus or pharmaceutically acceptable salts thereof along with one or more sugars. | 2013-04-18 |
20130095145 | Preparation for Transnasal Application - Disclosed is a preparation for transnasal application, which has improved fluidability. Specifically disclosed is a preparation for transnasal application, which comprises at least a complex comprising a fluidability-improving component comprising a first crystalline cellulose (A) having specified powder properties, tricalcium phosphate (B) having specified powder properties, and a second crystalline cellulose (C) having specified powder properties or a starch (D) having specified powder properties, and physiologically active substance. | 2013-04-18 |